Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Next Previous
Trial Profile

A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Hydrocortisone (Primary) ; Methotrexate (Primary) ; Selinexor (Primary) ; Venetoclax (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms SELCLAX

Most Recent Events

  • 21 Mar 2025 Status changed from recruiting to suspended.
  • 18 Dec 2024 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.
  • 16 Jan 2024 Planned End Date changed from 1 Jun 2024 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top